New and better drugs to treat diseases such as advanced breast cancer will have little effect on improving patient outcomes if a country does not have good healthcare structures in place, Professor Richard Sullivan told the Advanced Breast Cancer Third International Consensus Conference.
Without good systems, Prof Sullivan, of the Institute of Cancer Policy, King's Health Partners Comprehensive Cancer Centre, King's College London (UK), said there was little point in even discussing whether breast cancer drugs were affordable or not. "As things stand, I think many of the new molecular targeted agents are not affordable to many European countries, and this is only going to get worse."